Santen Pharmaceutical

4536.TApproved

Santen Pharmaceutical is a leading global player in the ophthalmology market, dedicated to addressing unmet medical needs in eye diseases. The company leverages its deep expertise in ocular drug delivery and formulation to build a diversified portfolio spanning glaucoma, retinal diseases, dry eye, and inflammation. With a long history of innovation and a commitment to research, Santen aims to contribute to the well-being of patients worldwide through its specialized ophthalmic solutions.

Market Cap

$3.4B

Employees

4000-5000

Focus

Biotech

4536.T · Stock Price

USD 1686.50+376.50 (+28.74%)

Historical price data

AI Company Overview

Technology Platform

Specialized expertise in ocular drug delivery systems and formulation technologies for topical and sustained-release ophthalmic products, including advanced solutions for anterior and posterior segment diseases.

Pipeline Snapshot

38 drugs in pipeline, 19 in Phase 3

Drug	Indication	Stage
Aflibercept Injection [Eylea]	Diabetic Macular Edema	Approved
Eybelis ophthalmic solution 0.002%	Normal Tension Glaucoma	Approved
DE-117B Eye Drops + Latanoprost	Open Angle Glaucoma	Phase 3
STN1013800 ophthalmic solution + STN1013800 ophthalmic solution Liquid Base, wit...	Blepharoptosis	Phase 3
DE-117 + Latanoprost ophthalmic solution	Open Angle Glaucoma or Ocular Hypertension	Phase 3

FDA Approved Drugs

VERKAZIANDAJun 23, 2021

Opportunities

Significant growth opportunities exist in the large and underpenetrated dry eye disease market, the development of sustained-release drug delivery systems for glaucoma, and expansion in high-growth geographic markets like China and the United States through new product launches.

Risk Factors

Key risks include clinical trial failures for late-stage pipeline assets, intense pricing competition and loss of exclusivity for core products, regulatory delays in major markets, and over-reliance on the Japanese market for a substantial portion of revenue.

Competitive Landscape

Santen competes with large pharmaceutical giants (Novartis, Roche) and specialized ophthalmic companies (Bausch + Lomb, Théa). Its primary differentiation is its pure-play focus on ophthalmology, enabling deep expertise, specialized R&D, and a dedicated global commercial network, complemented by a strong foundation in the Asian market.

Publications

Pipeline

FDA Approvals